Syncom Formulations (India) share price today

Syncom Formulations (India) Ltd's share price was ₹20.56 at the close on 4 November 2026. It has been rising for 9 weeks. That is 21.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹11 and ₹24, and at that close it sat 74% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Syncom Formulations (India) Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row.

Over the last 11 years the share price moved +764% while the NIFTY 500 moved +257%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

1. Best operating margin in 15 quarters

   Operating margin was 21% in the June 2026 quarter, against 14% a year earlier.

2. Profit up on a year earlier for 9 quarters in a row

   In the June 2026 quarter profit was ₹25 crore, +56.3% on a year earlier.

For April to June 2026 (the quarter ended 30 June 2026), Syncom Formulations (India) reported revenue of ₹126 crore, up 7.7% from ₹117 crore a year earlier, and a profit of ₹25.0 crore, up 56.3% from ₹16.0 crore.

Syncom Formulations (India) results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Syncom Formulations (India) closed at ₹20.56 on 4 November 2026, up 27.9% from ₹16.07 a year earlier (7 November 2025) and up 99.2% over five years. Its highest weekly close since February 2016 was ₹25.59 on 13 September 2024.

Syncom Formulations (India) share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

567 weekly closes from 26 February 2016 to 4 November 2026.

4 Nov 2026: Syncom Formulations (India) closed at ₹20.56, up 6.8% on the week and down 14.2% on the month. 23 Sep 2026: ex-date for a dividend of ₹0.10 a share.

Earlier

• Results for April to June 2026: Revenue up 7.7% and profit up 56.3% on a year earlier.

Syncom Formulations (India) paid ₹0.10 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.49% at the ₹20.56 close on 4 November 2026. The last was a dividend of ₹0.10 a share, ex-date 23 September 2026.

Syncom Formulations (India) dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Syncom Formulations (India) Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 7 of its last 10 reported years.

From the NSE corporate-actions record, read 5 November 2026.

Syncom Formulations (India)'s management made 0 promises we could check against what it later reported.

Our read after the April to June 2026 results, written 10 October 2026.

What is changing at Syncom Formulations (India), from the latest results and calls: operating profitability, lower financing exposure and domestic distribution stocking.

• Operating profitability. Operating profit increased faster than sales in the latest quarter. ⚠ estimate
• Lower financing exposure. Reported borrowings have declined. ✓ fact
• Domestic distribution stocking. Management links inventory accumulation to the domestic business. ✓ fact
• Improved operating cash conversion. Latest-year operating cash conversion exceeded the aggregate window. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the April to June 2026 results, written 10 October 2026.

I would abandon the margin-led progress thesis if the next comparable results showed revenue falling alongside operating profit, while inventory continued accumulating without operating cash conversion.

Each change stops working if

• Operating profitability: Operating profit declines on comparable sales, indicating that the improved profit per unit of revenue is reversing.
• Lower financing exposure: Borrowings rise to fund inventory or distributions while operating cash conversion falls.
• Domestic distribution stocking: Inventory grows without subsequent sales and collection improvement.
• Improved operating cash conversion: Supplier payment periods shorten before inventory and receivables release cash.

The main risks

• : Non-operating receipts contribute to reported profit. ⚠ estimate
• : Inventory and supplier financing require follow-through. ⚠ estimate
• : Accounting corrections and limited guidance reduce forecast precision. ⚠ estimate
• : The later outcome of the disclosed review and appeal remains unverified. ⚠ estimate

Our read after the April to June 2026 results, written 10 October 2026.

When Syncom Formulations (India) reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Operating margin declines while sales growth fails to compensate.

Syncom Formulations (India) is on 2 of our India lists: Penny stocks and Pharma stocks.

Syncom Formulations (India) Ltd earned ₹25.0 Cr of net profit in the Jun 2026 quarter, +56.3% on the same quarter a year earlier. That is the 9th quarter in a row of profit growth. Full-year FY26 profit was ₹76.0 Cr. Over 13 years profit has grown 21.6% a year on average. That is 19.8% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹16.0 Cr.

For the full year, FY26 profit was ₹76.0 Cr (+55.1% on the year before).

Why profit moved: revenue changed +7.7% on a year earlier and the margin moved +7.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +49.0% and revenue +1.9%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Syncom Formulations (India) Ltd reported ₹126 Cr of revenue in the Jun 2026 quarter, +7.7% on the same quarter a year earlier. Over 13 years it has grown 11.8% a year on average. The last full year, FY26, came in at ₹488 Cr. The last four reported quarters add to ₹498 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹488 Cr, +5.4% on the year before.

Recent pace: the last four quarters grew +1.9% on average, against 11.8% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +0.4%, against +30.8% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +48.3%, against +72.2% a year (rolling over).

Syncom Formulations (India) Ltd's operating margin was 21.0% in the Jun 2026 quarter, 7.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 10 years it has been between 9.0% and 16.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +7.4 percentage points on the year while gross margin changed +6.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 50% of Syncom Formulations (India) Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹58.0 Cr of operating cash against ₹76.0 Cr of profit. After ₹66.0 Cr of spending on assets, free cash was −₹8.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Why this happened. This improvement supports a better cash outcome than the earlier negative operating cash period. Longer supplier payment periods also contributed to the shorter cash cycle, so the benefit depends partly on supplier terms.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 50% of profit came in as cash: the cash cycle got 41 days longer between FY17 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 41 days longer. The next section looks at where the cash is stuck.

Syncom Formulations (India) Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 68 days in FY26, up from 27 days in FY17. It spent ₹84.0 Cr on assets over the last 3 years. Customers take 83 days to pay, and stock sits for 81 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹488 Cr, each day of that cycle ties up about ₹1.3 Cr, so roughly ₹91.0 Cr is tied up in the business at any time.

FY26: customers took 83 days to pay and stock sat for 81 days, about 2.7 months of sales sitting as stock, for a full cycle of 68 days, longer than FY17's 27.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 81 days. Customers pay about 83 days after that. Suppliers are paid at 96 days. Together that makes the 68-day cycle.

Spending on assets: ₹84.0 Cr over the last 3 years, against ₹17.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Syncom Formulations (India) Ltd's P/E is 22.7×, in the middle of its own history: higher than 53% of past readings. Its usual P/E (the middle reading) is 20.2×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.